DadFinStart your free week
DadFin › Stocks › Healthcare › MRVI

Maravai LifeSciences Holdings, Inc (MRVI) stock score

Healthcare · Biotechnology · United States

$7.44 ▲ +3.19% today

53.0
Dad Score, out of 100
middling

Maravai LifeSciences Holdings, Inc (MRVI) is a Biotechnology company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 53.0 out of 100 on the Dad Score, a middling reading that places the business ahead of 53% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #391 of 974. Its strongest axes are valuation and price action; its weakest are quality and growth.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Above average
Quality
Weak
Growth
Weak
Price action
Strong
Risk
Weak
Conviction
Weak
Liquidity
Average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)-80.4×
Dividend yield0.00%
Return on capital-14.9%
Operating margin-29.4%
Revenue growth (YoY)-28.3%
FCF yield-2.2%
Net debt / EBITDA3.00×
Piotroski F-Score1 / 9
52-week change+153.2%
Market cap$2.9B
Next earnings—

What subscribers see on MRVI

Start your free weekSubscriber? Open the full research →

Biotechnology peers

StockCompanyDad ScoreBandMarket cap
VRTXVertex Pharmaceuticals Incorporate51.2middling$127.8B
MRNAModerna, Inc.23.4weak$75.9B
REGNRegeneron Pharmaceuticals, Inc.91.1strong$75.7B
ARGXargenx SE55.1middling$57.5B
RVMDRevolution Medicines, Inc.40.6middling$44.3B
ONCBeOne Medicines AG94.5strong$40.7B
RPRXRoyalty Pharma plc70.8good$33.0B
ALNYAlnylam Pharmaceuticals, Inc.83.8good$29.4B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.